GnRHR is overexpressed in hormone-related cancers (e.g., 80% of ovarian cancer, 85% of endometrial cancer, 50% of breast cancer, and 86% of prostate cancer), as well as hormone-unrelated cancers (e.g., melanoma, glioblastoma, lung cancer and pancreatic cancer) [32,33,34]. Here, GNRHR is linked to melanoma.